Nilotinib

• Background:

  Nilotinib is a potent and selective Bcr/Abl tyrosine kinase inhibitor, as well as, an inhibitor of JAK2/STAT5, and MDM2 at the post-translational level. Nilotinib shows antiproliferative and antitumor effects in vivo.

• Description:

  BCR-ABL kinase inhibitor

• Product Name Alternative:

  4-methyl-N-[3- (4-methylimidazol-1-yl) -5- (trifluoromethyl) phenyl]-3-[ (4-pyridin-3-ylpyrimidin-2-yl) amino]benzamide

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Cancer | Apoptosis | Cancer Growth Inhibitors | Tyrosine Kinase Inhibitors

• Purity:

  ≥99%

• Weight:

  0.005

• Format:

  Crystalline powder

• Solubility:

  Soluble in DMSO (50 mg/ml), chloroform, DMF (~3 mg/ml), water(very poorly soluble, maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility), and ethanol(very poorly soluble)

• Molecular Formula:

  C28H22F3N7O

• Molecular Weight:

  529.5

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Gallipoli P., et al. (2014) Blood. 2. Zhang H., Gu L., Liu T., Chiang K.Y., & Zhou M. (2014) PloS One. 9(6): e100960.

• CAS Number:

  641571-10-0